Good news! Third dose can give Omicron vaccine’s effectiveness a big boost, study finds

New Delhi: In what could be described as a great relief amid growing cases of the new variant of Covid Omicron, a new study published in the UK Health Security Agency (UKSHA) shows that a third dose of the Covid-19 vaccine may increase the one person’s resistance to the Omicron variant up to 88 percent. Eric Topol, professor of molecular medicine and director of the Scripps Research Translational Institute in the United States, informed that the vaccine’s efficacy drops to 52% against Omicron about six months after taking the second injection of a COVID-19 vaccine.Read also – United Kingdom: Omicron “clearly softer”, no new measures necessary, says Prime Minister Boris Johnson

Topol took to Twitter and wrote: “This is a big boost for the protection of the 3rd dose vaccine from hospitalization against Omicron infection. The efficacy of the vaccine decreased from 52% (due to the decrease in 2 doses after 6 months) to 88% after the 3rd dose. Read also – After Mumbai, Thane decides to close schools in grades 1 to 9 until January 31

Also read – US FDA clears Pfizer’s Covid-19 booster vaccine for 12-15 year olds | Details here

“It is quite impressive that the vaccines directed against the ancestral strain peak of 2 years ago, with the virus that has evolved through more than 290 million confirmed cases, and now to the hyper-mutated Omicron, have retained nearly 90 percent effectiveness against severe disease. with a 3rd hit, ”he said in another tweet.

This latest study comes at a time when the world is fighting against the new variant of covid, Omicron. Previously, reports had suggested that the effectiveness of the second dose wanes after a period of six months. Therefore, according to the latest study, the third dose will offer a significantly higher degree of protection against the last mutated strain.

However, it is important to note that despite the estimated reduction in the risk of hospitalization and the preserved efficacy of the vaccine against hospitalization, the study authors noted that there may still be a large number of admissions. to the hospital.

According to the UKHSA report, two different studies looked at the association between two COVID variants (Omicron and Delta) and vaccine status and risk of hospitalization.

First study

  • The first study was based on around half a million Omicron cases from all age groups
  • The first study confirms the previous finding of a reduction in the overall risk of hospitalization for Omicron compared to the Delta variant.
  • The first study found a substantial reduction in the risk of hospitalization for Omicron cases after three doses of the vaccine compared to those who were not vaccinated.

Second study:

  • The second used a smaller data set and is limited to people aged 18 and over.
  • The second study also found a substantial reduction in the risk of hospitalization for Omicron cases after three doses of the vaccine compared to those who were not vaccinated.



Source link

Sara H. Byrd